Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years
2014 · Leukemia · 129 citations
https://doi.org/10.1038/leu.2014.332
T
Thomas Pabst
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
365
Papers
10.6K
Citations
46
h-index
144
i10-index
Thomas Pabst is an academic researcher from University of Bern. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Multiple Myeloma Research and Treatments & Hematopoietic Stem Cell Transplantation. The author has an h-index of 46, co-authored 311 publications.
ORCID: 0000-0002-6055-5257Papers by this author
worksPost-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
2015 · The Lancet Haematology · 99 citations
https://doi.org/10.1016/s2352-3026(15)00148-9
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
2016 · Leukemia · 65 citations
https://doi.org/10.1038/leu.2016.183
CAR T-cell therapy and critical care
2021 · Wiener klinische Wochenschrift · 42 citations
https://doi.org/10.1007/s00508-021-01948-2
Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission—Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
2016 · Cancer · 37 citations
https://doi.org/10.1002/cncr.30400
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
2023 · BMC Cancer · 37 citations
https://doi.org/10.1186/s12885-023-10824-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat